Erman Akkus: How Genetic Testing Revolutionizes Care for Young Breast Cancer Survivors and Advances in Anaplastic Thyroid Carcinoma Treatment
Erman Akkus, Medical Oncology Fellow at Ankara University, shared on X/Twitter:
“1. Second primary breast cancer among young (≤40 year) stage 0-III breast cancer survivors: a study of JAMA
At median 10 years:
2.2% for women who did not carry a germline pathogenic variant
8.9% for carriers of a pathogenic variant
PV (pathogenic variant) carriers vs non carriers sHR (sub-hazard ratio): 5.27( 1.43-19.43)
Importance of germline genetic testing in young women with breast cancer!
Source: Erman Akkus/X
2. Pembrolizumab in addition to Dabrafenib/Trametinib for BRAFV600E-mutated anaplastic thyroid carcinoma: a study by Thyroid Journal
Pembrolizumab added upfront or at progression vs dabra-trame alone
mOS: 17 vs 9 mo, p=0.03
mPFS: 11 vs 4 mo, p=0.04
If dabra-trame given as neoadjuvant (before surgery), mOS: 63 mo.”
Source: Erman Akkus/X
About OncoDaily
OncoDaily was founded in 2023. It is a US-based oncology media platform, which features the latest news, insights, and patient stories from the world of oncology. Within a short period of time it became one of the leading oncology media platforms globally.
OncoDaily gathers content from various sources, including social media posts from renowned oncologists from all over the world, news from oncology societies and cancer centers, patient and survivor stories, and career-related information for professionals.
The mission of OncoDaily is to empower patients, survivors, and professionals with the knowledge and inspiration they need to fight cancer. The motto of OncoDaily is “Cancer doesn’t take a day off – neither do we.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023